Table 1 Osteoporosis features in the study analysis population as a function of diagnostic criterion for osteoporosis
From: Management of osteoporosis and associated quality of life in post menopausal women
Low BMD only N = 752 | Fracture only N = 189 | Both low BMD and fracture N = 365 | p | Total N = 1,306 | |
|---|---|---|---|---|---|
Age at inclusion (mean ± SD; years) | N = 750 64.3 ± 8.4 | N = 189 70.6 ± 9.6 | N = 365 67.7 ± 8.671 | ≤ 0.001 | N = 1304 66.2 ± 8.9 |
Age at menopause (mean ± SD; years) | N = 745 49.8 ± 4.0 | N = 187 50.0 ± 3.6 | N = 360 49.3 ± 4.3 | 0.218 | N = 1290 49.7 ± 4.0 |
Time since menopause (mean ± SD; years) | N = 745 14.5 ± 8.7 | N = 187 20.6 ± 9.5 | N = 360 18.3 ± 9.9 | ≤ 0.001 | N = 1290 16.5 ± 9.4 |
At least one risk factor for osteoporosis | 564 (75.0%) | 156 (82.5%) | 308 (84.4%) | ≤ 0.001 | 1,028 (78.7%) |
Osteoporosis treatment ongoing at time of consultation | 427 (56.8%) | 118 (62.4%) | 240 (65.8%) | 0.016 | 785 (60.1%) |
Nature of ongoing treatment | N = 407 | N = 111 | N = 228 | N = 746 | |
Bisphosphonates | 295 (72.5%) | 084 (75.7%) | 164 (71.9%) | 0.895 | 543 (72.8%) |
Selective estrogen receptor modulator | 53 (13.0%) | 7 (6.3%) | 16 (7.0%) | 0.023 | 76 (10.2%) |
Strontium ranelate | 54 (13.3%) | 18 (16.2%) | 47 (20.6%) | 0.062 | 119 (16.0%) |
Other | 14 (3.5%) | 6 (5.4%) | 6 (2.7%) | 0.056 | 26 (3.5%) |
Calcium or vitamin D supplementation | N = 597 609 (82.3%) | N = 153 161 (86.6%) | N = 324 316 (87.8%) | 0.008 | N = 1064 1086 (84.5%) |